Taiwan Firm AHEAD Medicine Disrupting cell analysis with AI to help accelerate disease diagnostics and cell therapy worldwide

AHEAD Medicine’s AI platform removes bottlenecks in drug discovery, clinical trials, and patient treatment, increasing speed, accuracy, and reproducibility. TAIPEI, July 28, 2022 /PRNewswire/ — AHEAD Medicine, a UC Berkeley SkyDeck-backed company has launched a new AI-enabled cell immuno-profiling analysis platform. The platform unlocks the cell-level data critical to vaccine, therapeutic research & development, patient … Read more